Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2009

View Archived Issues

Triamcinolone acetonide phase III SCORE study results in macular edema reported

Novo Nordisk to assess insulin analogue NN-1250 in phase III trials in type 1 and 2 diabetes

Inhaled AIR-645 well tolerated in phase I study

Phase II data for p53-SLP vaccine in ovarian cancer reported

BIBF-1120 maintenance therapy may delay disease progression in ovarian cancer

Ono's oral antidiabetic Glactiv tablet approved in Japan

AstraZeneca submits MAA in Europe for Vimovo

FDA approves GSK's cervical cancer vaccine for girls and young women aged 10-25 years

FDA approves Crestor for pediatric heterozygous familial hypercholesterolemia

AstraZeneca and Astellas' Symbicort Turbuhaler approved in Japan for asthma

FDA authorizes Diatherix Laboratories' H1N1-09 influenza test for emergency use

Transgenomic licenses Cold-PCR technology from Dana-Farber Cancer Institute

TcLand Expression starts study of K-RejX test in kidney transplant recipients at risk of CAMR

Med BioGene reports results from validation study of LungExpess Dx in NSCLC

Epigenomics launches Epi proColon diagnostic blood test for colorectal cancer in Europe

Vitae Pharmaceuticals describes 11beta-HSD1 inhibitors for the treatment of diabetes

Novel oncolytic compounds disclosed by Columbia University

Gruenenthal claims ORL1 and mu-opioid receptor ligands for the treatment of pain

Takeda receives Japanese approval for additional indication for Basen

FDA approves Elitek for management of plasma uric acid levels in cancer patients

Rexahn reports topline phase IIa data for Serdaxin in major depressive disorder

K-101 topical solution eradicates infection in adults with distal subungual onychomycosis

Dainippon Sumitomo's Miripla granted Japanese manufacturing and marketing approval

GnRH antagonist elagolix sodium improves endometriosis symptoms in Petal study

Diabetes candidate drug DSP-7238 shows selective and sustained DPP IV inhibition

Patupilone active against breast cancer brain metastases

BNC-210 exhibits anxiolytic and antidepressant activity in preclinical studies in rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...